Category - Developments

Lipocine (NASDAQ:LPCN) announced receipt of $10-million in January by means of a loan and security agreement with Silicon Valley Bank. “This debt facility strengthens our balance sheet and provides increased...

Profound Medical (OTCQX:PRFMF; TSXV:PRN) has completed patient enrollment in the TACT pivotal study designed to further evaluate safety and efficacy of its TULSA-PRO medical device to ablate prostate tissue in patients...

Ortho Regenerative Technologies (CSE:ORTH) announced that a peer-reviewed article detailing the tissue regeneration properties of its implants was published in the current issue of Journal of Tissue Engineering and...

Pixium Vision (FR0011950641-PIX) announced the first successful human implantation and activation of PRIMA, its new generation miniaturized wireless photovoltaic sub-retinal implant, in a patient with severe vision loss...

Titan Pharmaceuticals (NASDAQ:TTNP) is in discussions with Braeburn Pharmaceuticals about their partnership for the development and commercialization of Probuphine, the first six-month maintenance treatment of opioid...

NeutriSci International (OTCQB:NRXCF; TSX-V:NU; FRANKFURT:1N9) and Scientus Pharma have entered into a major R&D memorandum of understanding to share their technologies to develop, test, produce, and distribute a...

Profound Medical (OTCQX:PRFMF; TSXV:PRN) expects revenue of about  $1.9-million for the fourth quarter of 2017, compared to nil in the year earlier quarter, and up about 30% sequentially from the third quarter of 2017...

Eiger BioPharmaceuticals (NASDAQ:EIGR) completed enrollment of the Phase 2 ULTRA study designed to evaluate the effects of ubenimex in patients with primary and secondary lymphedema of the lower limbs. A total of 54...

Ortho Regenerative Technologies (CSE:ORTH.CN) announced that a peer-reviewed article entitled, “Freeze-Dried [Ortho-R] Injectable Surgical Implants for Meniscus Repair: Pilot Feasibility Studies in Ovine...

Hutchison China MediTech (AIM, NASDAQ:HCM) has initiated a U.S. Phase 1 bridging clinical trial of fruquintinib, a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors 1, 2 and 3...